SUPN Overview
Upcoming Projects (SUPN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (SUPN)
-
A prescriber check-in on AbbVie's Vyalev (foscarbidopa + foslevodopa) for Advanced Parkinson's Disease
Tickers: ABBV, SUPN, MSBHF
Executed On: Apr 25, 2025 at 11:00 AM EDT -
Discussing Supernus' FDA approval of ONAPGO (apomorphine hydrochloride), subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.
Ticker: SUPN
Executed On: Feb 07, 2025 at 12:00 PM EST -
Reviewing the data from Supernus Pharmaceuticals exploratory open-label Phase 2a clinical study of SPN-820 in adults with major depressive disorder.
Ticker: SUPN
Executed On: Oct 31, 2024 at 08:30 AM EDT
Expired Projects (SUPN)
-
What Can We Expect from the Phase 2b Data of Supernus' ADHD drug SPN-812?
Ticker: SUPN
Execute By: Nov 18, 2016
Upcoming & Overdue Catalysts (SUPN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (SUPN)
-
Supernus (SUPN) Announces Early Release of Top-Line Phase 2b Data Evaluating ADHD drug SPN-812
Ticker: SUPN
Occurred on: Oct 11, 2016 -
Supernus Receives FDA Tentative Approval for Expanded Label of Trokendi XR to Include Migraine Prophylaxis in Adults
Ticker: SUPN
Occurred on: Aug 19, 2016
Strategic Initiatives (SUPN)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
